$TEM

LEFKOFSKY ERIC P sold $1.1M of TEM (indirect holdings)

LEFKOFSKY ERIC P (CEO and Chairman) sold 24,318 indirectly-held shares of Tempus AI, Inc. (TEM) at $46.89 ($1.14M total) on 2026-05-27 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · LEFKOFSKY ERIC P
Published May 29, 2026, 8:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 29, 2026, 8:20 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$TEM
Neutral
medium confidence
Mentioned
$TEM
Relevance
7/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TEMNeutralLow
01

Why it matters

Open-market insider sales can pressure sentiment, but 10b5-1 pre-arranged plans typically limit the inference traders draw about near-term fundamentals.

02

Market read

Traders may monitor for follow-on insider activity, but this specific disclosure is unlikely to be a standalone catalyst.

03

What to watch

The filing does not provide context on total insider selling cadence, whether other insiders sold/bought, or whether the sale size is large relative to holdings beyond the post-transaction balance.

Relevance 7/10Novelty 4/10Timing: SEC Form 4 filed May 29 covering sales executed May 27

Background

The article is an SEC Form 4 insider transaction disclosure for Tempus AI, Inc.

Company-level read

Ticker impact

$TEMNeutralMedium confidence
Context

Tempus AI CEO/Chairman and 10% owner LEFKOFSKY Eric P sold $1.14M of TEM shares via an open-market transaction under a 10b5-1 plan.

Expected impact

Low probability of a sustained price move; any reaction is likely short-lived unless accompanied by other catalysts.

Evidence & confidence

The filing is a routine insider transaction and explicitly states a pre-arranged Rule 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

Minimal; this is company-specific insider activity with no stated sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish fundamentals.

Key entities

  • Tempus AI, Inc.

    Subject of the Form 4 insider sale; CEO/Chairman and 10% owner sold shares under a 10b5-1 plan.

  • LEFKOFSKY ERIC P

    CEO and Chairman; executed an open-market sale of 24,318 shares at $46.8900.

Related articles

$TEMMed

Why Is Tempus AI Stock Surging on Friday? - Tempus AI (NASDAQ:TEM)

Tempus AI Inc. (NASDAQ:TEM) shares rose about 11% on Friday, outperforming the Nasdaq and the Healthcare sector, amid an AI-healthcare sector rally. The move followed strong peer results, including Doximity’s fiscal Q1 revenue of $156.6 million, and a strategic collaboration with CellCarta adding Tempus to its CDx lab network. TEM traded near $50.95.

$TEMMed

BTIG cuts Tempus AI stock price target to $70 on model update

BTIG cut its Tempus AI (NASDAQ:TEM) price target to $70 from $80 while keeping a Buy rating after the company’s Q2 2026 earnings call. Tempus AI reported 22% YoY revenue growth, raised 2026 revenue guidance to 25% to 26%, and posted $382.5M revenue with an adjusted EPS loss of $0.04. BTIG cited Tempus’s $1.5B Personalis deal with a $46 stock-price termination trigger.

$TEMMedAI 8/10

Dear Tempus AI Stock Fans, Mark Your Calendars for July 30

Tempus AI (NASDAQ: TEM) agreed to acquire Personalis (PSNL) for $16.25 per share in stock, valuing the deal at about $1.5 billion enterprise value net of Tempus’ existing stake, with closing expected late 2026 or early 2027. Tempus expects integration to expand MRD capabilities. After the July 20 announcement, TEM fell 7.74% intraday. In Q1, revenue rose 36.1% to $348.12M. Needham reiterated Buy at $75; consensus target is $66.75.

$TEMMedAI 8/10

Tempus AI Raises FY2026 Sales Guidance to $1.595B-$1.605B

Tempus AI (NASDAQ: TEM) has raised its full-year 2026 sales guidance, signaling robust demand for its artificial intelligence-driven healthcare solutions. The company updated its revenue outlook to a range of $1.595 billion to $1.605 billion, an increase from the previous guidance of $1.590 billion to $1.600 billion.

$TEMMedAI 8/10

Tempus AI Q2 Results: Revenue rises 22% YoY, stock slides

Tempus AI (NASDAQ: TEM) reported second-quarter revenue of $382.5 million, rising 22% year-over-year and surpassing Street consensus estimates of $379.7 million. Despite the top-line beat and a narrower-than-expected loss per share of four cents versus an estimated 14 cents loss, shares declined 2.4% in after-hours trading to $43.25.